Growth Metrics

Omeros (OMER) Other Gross PP&E Adjustments (2011 - 2026)

Omeros recorded quarterly Other Gross PP&E Adjustments of $2.0 million in Q1 2026, up 196.09% quarter-over-quarter from $690000.0 in Q4 2025, and up 183.73% year-over-year from $720052.0 in Q1 2025.

Omeros' Other Gross PP&E Adjustments history runs 16 years deep, the most recent figure standing at $2.0 million for Q1 2026.

  • In Q1 2026, Other Gross PP&E Adjustments rose 183.73% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (up 183.73% YoY), while the FY2025 annual figure was $690000.0, up 118.1% from the prior year.
  • Other Gross PP&E Adjustments came in at $2.0 million for Q1 2026 at Omeros, up from $690000.0 in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $2.0 million in Q1 2026 to a low of -$18.7 million in Q1 2022.
  • A 5-year average of -$7.7 million and a median of -$7.8 million in 2024 frame the typical range for Other Gross PP&E Adjustments.
  • Across the five-year window, Other Gross PP&E Adjustments advanced 5.49% in 2022 and jumped 183.73% in 2026, its largest moves.
  • Omeros' Other Gross PP&E Adjustments stood at -$15.1 million in 2022, then soared by 34.12% to -$10.0 million in 2023, then jumped by 61.79% to -$3.8 million in 2024, then jumped by 118.1% to $690000.0 in 2025, then soared by 196.09% to $2.0 million in 2026.
  • According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered $2.0 million, $690000.0, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Gross PP&E Adjustments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -83,048.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -60,691.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -285.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -892,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -1.69 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -189.30 Mn
10 Omeros 772.03 Mn 636.71 Mn 9.31 Mn 2.04 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 2.04 Mn
Mar 31, 2026 2.04 Mn
Dec 31, 2025 690,000.00
Dec 31, 2025 690,000.00
Sep 30, 2025 1.08 Mn
Sep 30, 2025 1.08 Mn
Jun 30, 2025 -694,000.00
Jun 30, 2025 -694,000.00
Mar 31, 2025 -2.44 Mn
Mar 31, 2025 -2.44 Mn
Dec 31, 2024 -3.81 Mn
Dec 31, 2024 -3.81 Mn
Sep 30, 2024 -4.52 Mn
Sep 30, 2024 -4.52 Mn
Jun 30, 2024 -7.33 Mn
Jun 30, 2024 -7.33 Mn
Mar 31, 2024 -7.83 Mn
Mar 31, 2024 -7.83 Mn
Dec 31, 2023 -9.98 Mn
Dec 31, 2023 -9.98 Mn
Sep 30, 2023 -10.71 Mn
Sep 30, 2023 -10.71 Mn
Jun 30, 2023 -11.57 Mn
Jun 30, 2023 -11.57 Mn
Mar 31, 2023 -13.87 Mn
Mar 31, 2023 -13.87 Mn
Dec 31, 2022 -15.15 Mn
Dec 31, 2022 -15.15 Mn
Sep 30, 2022 -13.20 Mn
Sep 30, 2022 -13.20 Mn
Jun 30, 2022 -14.95 Mn
Jun 30, 2022 -14.95 Mn
Mar 31, 2022 -18.70 Mn
Mar 31, 2022 -18.70 Mn
Dec 31, 2021 -28.84 Mn
Dec 31, 2021 -28.84 Mn
Sep 30, 2021 -22.55 Mn
Sep 30, 2021 -22.55 Mn
Jun 30, 2021 -24.30 Mn
Jun 30, 2021 -24.30 Mn
Mar 31, 2021 -19.79 Mn
Mar 31, 2021 -19.79 Mn
Dec 31, 2020 -25.91 Mn
Dec 31, 2020 -25.91 Mn
Sep 30, 2020 -21.39 Mn
Sep 30, 2020 -21.39 Mn
Jun 30, 2020 -19.97 Mn
Jun 30, 2020 -19.97 Mn
Mar 31, 2020 -22.21 Mn
Mar 31, 2020 -22.21 Mn
Dec 31, 2019 -27.18 Mn
Dec 31, 2019 -27.18 Mn
Sep 30, 2019 -15.17 Mn
Sep 30, 2019 -15.17 Mn
Jun 30, 2019 -10.67 Mn
Jun 30, 2019 -10.67 Mn
Mar 31, 2019 -11.76 Mn
Mar 31, 2019 -11.76 Mn
Dec 31, 2018 -879,000.00
Dec 31, 2018 -879,000.00
Dec 31, 2017 -2.43 Mn
Dec 31, 2017 -2.43 Mn
Dec 31, 2016 -7.19 Mn
Dec 31, 2016 -7.19 Mn
Dec 31, 2015 -4.75 Mn
Dec 31, 2015 -4.75 Mn
Dec 31, 2014 -2.73 Mn
Dec 31, 2014 -2.73 Mn
Dec 31, 2013 -738,000.00
Dec 31, 2013 -738,000.00
Sep 30, 2013 -467,000.00
Sep 30, 2013 -467,000.00
Jun 30, 2013 -373,000.00
Jun 30, 2013 -373,000.00
Dec 31, 2012 412,000.00
Dec 31, 2012 412,000.00
Dec 31, 2011 1.71 Mn
Dec 31, 2011 1.71 Mn